Volume 41, Number 10, October 2021

Contents

Reviews


Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. A. GADDUCCI, S. COSIO (Pisa, Italy) ................................................................. 4673

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm? N. FUJIMOTO, K. HARADA, M. SHIOTA, I. TOMISAKI, A. MINATO, Y. NAGATA, R. KIMURO, M. HARADA, M. FUJISAWA (Kitakyushu; Kobe; Fukuoka, Japan) ................................................................. 4687


Fascial Organisation and Lymphatic Systems Around the Pelvic Floor: A Literature Review. K. SATO, T. MIURA, Y. SAKAMOTO, H. MOROHASHI, K. HAKAMADA (Aomori; Hokkaido, Japan) ................................................................. 4705

Experimental Studies

The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model. N.F. WU, J. YAMAMOTO, Y. AOKI, N. MASAKI, C. SAMONTE, J. WU, M. BOUVET, R.M. HOFFMAN (San Diego, CA; Cambridge, MA, USA) ........................................................................ 4715

Contents continued on the back cover
Announcement - Call for Papers

Special Issue of ANTICANCER RESEARCH 2021 on NEW ANTICANCER AGENTS

TOPICS:

A. Experimental Studies on “New Anticancer Agents”
   1. Synthesis and evaluation in vitro and in vivo
   2. Mechanism of action
   3. Reversal of resistance to anticancer agents
   4. Oncolytic viruses

B. Clinical Studies on “New Anticancer Agents”
   1. Pharmacology
   2. Clinical trials
   3. Combination chemotherapy
   4. Immunotherapeutic agents
   5. New methodologies in drug delivery
   6. Vaccines

Deadline for submission of original and review articles: October 10, 2021
Publication date: December 2021

Information:
Dr. George J. Delinasios, e-mail: journals@iiar-anticancer.org
Reviews